HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jang, I.-K. Search for Related Content PubMed PubMed Citation Articles by Jang, I.-K.

A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with Novastan and TPA (MINT) study

Ik-Kyung Jang, MD, FACC^a, David F. M. Brown, MD^a, Robert P. Giugliano, MD, SM^a, H. Vernon Anderson, MD, FACC^*, Douglas Losordo, MD, FACC, Jose C. Nicolau, MD, Oscar P. Dutra, MD, Oscar Bazzino, MD, FACC^||, Victor Molina Viamonte, MD, FACC^¶, Roberto Norbady, MD^**, Alvaro Sosa Liprandi, MD, Thomas J. Massey, BS, Robert Dinsmore, MD^a, Richard P. Schwarz, Jr, PhD the MINT Investigators

^a Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
^* Texas Heart Institute, Houston, Texas, USA
St. Elizabeth Hospital, Boston, Massachusetts, USA
Instituto de Mol stias Cardiovascular, Sao Jose Do Rio Preto, Brazil
Instituto de Cardiologica, do Rio Grande do Sul, Porto Alegre, Brazil
^|| Hospital Italiano, Buenos Aires, Argentina
^¶ Institute de Cardiologica y Cirugia Cardiovascular, Hospital Espanol, Buenos Aires, Argentina
^** Hospital Frances, Buenos Aires, Argentina
Sanatorio Mitre, Buenos Aires, Argentina
Coromed Inc., Troy, New York, USA
Texas Biotechnology Corporation, Houston, Texas, USA

View larger version (14K): [in a new window]   Figure 1 Study design. One hundred twenty-five patients were randomized in a 1:1:1 ratio to heparin, low-dose argatroban and high-dose argatroban therapy. Heparin was administered as a bolus of 70 U/kg over 1 min followed by an infusion of 15 U/kg/h. A bolus of 100 µg/kg of argatroban was given over 1 min followed by an infusion of either 1.0 µg/kg/min or 3.0 µg/kg/min. ASA, aspirin. *TIMI grade 3 flow and corrected TIMI frame count.

View larger version (20K): [in a new window]   Figure 2 TIMI grade 3 flow at 90 min. TIMI grade 3 flow was observed in 42.1% (16/38) of heparin patients, 56.8% (21/37) of low-dose argatroban (p = 0.20 vs. heparin) and 58.7% (27/46) of high-dose argatroban patients (p = 0.13 vs. heparin patients).

View larger version (33K): [in a new window]   Figure 3 TIMI grade 3 flow at 90 min in patients presented 3 h and >3 h. For the patients who presented late, between 3 and 6 h from the pain onset, TIMI grade 3 flow was achieved significantly more frequently in the high-dose argatroban group as compared with the heparin group: 20.0% of heparin, 50.0% of low-dose argatroban and 57.1% of high-dose argatroban patients (p = 0.03 vs. heparin). White bars, heparin; black bars, low-dose argatroban; gray bars, high-dose argatroban.